NCT00738777 - Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2024

Conditions

Breast Cancer

Interventions

DRUG

Anastrozole

1 mg,QD,PO

DRUG

Anastrozole+Fulvestrant

Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter

DRUG

Tamoxifen

loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO

DRUG

Tamoxifen

loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO

Trial Locations (4)

Medisch Centrum Haaglanden, The Hague

St. Antonius ziekenhuis, Nieuwegein

UMC St. Radboud, Nijmegen

NKI-AVL, Amsterdam